Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy

Abstract

Background Measurement of anti-SARS-CoV-2 RBD Ig G antibody response is very important to define the dynamics of immunization in vaccine COVID-19 recipients. Materials and methods Sera from four BNT162b2 vaccine recipients who erroneously received vaccine overdose were analyzed at different time-points. Results At 6 days the serum increase of antibodies was analogous for the three SARS-CoV-2 naïve recipients. At 14 days the antibody level increased and reached a peak, though showing a different pattern among the three recipients. At 21 days the serum antibody level started to decrease from its maximum value. The data for the previously infected recipient were in agreement with values found in COVID-19 positive receivers. Thus, after the single prime-dose of vaccine, the elicited antibody response was similar to prime-boost vaccination in naïve recipients. Conclusions In spite of the overdosage, this study confirms the efficiency of the BNT162b vaccine in eliciting a sustained antibody response as heterologous boost-vaccine in previously Oxford/AstraZeneca vaccinated recipients, as well as, prime-vaccine in COVID-19 infected receivers. Importantly, the humoral immune response of recipients was not proportional to the vaccine overdose. Nonetheless, we cannot portray a univocal effect of vaccine overdose concerning anti-SARS-CoV-2 antibody response because the values found were highly heterogeneous.

The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study

“…The total seropositivity rate of serum IgM and IgG antibodies in August in the present study population was higher than that in February and March, and the serum IgG and IgM antibody levels gradually decreased over time in September and October. This decline suggested that the IgG antibody could not maintain at a higher level for a longer time in the body, and it is necessary to strengthen vaccination [6,23]. After beginning the booster vaccination at the end of October in Beijing, the IgG antibody seropositivity rate in November increased compared with that in September and October.…”

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan

“…Overdose with the BNT162b2 vaccine injections has been reported in Australia, Germany, Italy, and the United States. 6 In this study, we reported 25 recipients who erroneously received undiluted BNT162b2 vaccine and adverse events and laboratory abnormalities were prospectively monitered.…”

Anti‐SARS‐CoV‐2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID‐19 vaccination regimens

“…The currently available data suggest that the primary series of prime‐boost heterologous vaccination combination of AZ/PZ and rAd26/rAd5 (Sputnik) induce a strong and broad immune response in healthy individuals. 23 , 24 , 25 , 26 , 27 , 28 , 29 Immunogenicity data on other heterologous vaccination regimens (i.e., 2SV with AZ or PZ booster), however, are limited.…”